Jan Mikkelsen, Ascendis Pharma president and CEO
March 14, 2022 07:16 AM EDT
R&D

Af­ter first FDA win last year, As­cendis touts a new PhI­II suc­cess in hy­poparathy­roidism

Max Gelman

Senior Editor

Af­ter achiev­ing its first FDA ap­proval last sum­mer, As­cendis Phar­ma be­lieves it’s ap­proach­ing a sec­ond in the near fu­ture.

The Dan­ish biotech tout­ed topline …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

A service from the Financial Times